Biogen (BIIB) announced new data that it says reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy. These latest findings from Part C ...

US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of ...

New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Many SMA patients continue to see gains in motor function with long-term Spinraza treatment, a real-world study from ...